U.S., Dec. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07300150) titled 'A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors' on Dec. 10.
Brief Summary: The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of PT0511 in adult participants with solid tumors as monotherapy and in combination with cetuximab in participants with colorectal cancer (CRC).
Study Start Date: Nov. 21
Study Type: INTERVENTIONAL
Condition:
Colorectal Cancer
Pancreatic Cancer
Non-Small Cell Lung Cancer
Solid Tumor
Intervention:
DRUG: PT0511
Intravenous infusion.
DRUG: Cetuximab
In...